GlassScriptPhysician profile
Norman A Lockshin
NPI 1366440117
$1,471.10
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $295 · 2021: $31.46 · 2023: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $268.21 | 2019-2021 | |
| Abbvie INC. | $253.72 | 2019-2023 | |
| Galderma Laboratories, L.P. | $206.53 | 2019-2020 | |
| Dermavant Sciences, INC. | $125.01 | 2023 | Vtama |
| Celgene Corporation | $92.22 | 2019 | |
| Pfizer INC. | $87.05 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $76.45 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $60.55 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $58.94 | 2019-2020 | |
| Genzyme Corporation | $55.96 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.86 | 2019 | |
| Leo Pharma INC. | $39.57 | 2019 | |
| Ucb, INC. | $21.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.39 | 2019 | |
| Epi Health, LLC | $19.40 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $19.17 | 2019 | |
| Lilly USA, LLC | $16.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Lockshin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.